A 9-year-old Woburn maker of proteins for research and diagnostic tests has gotten a $3.5 million equity investment from a Chinese biotech under a partnership to develop drugs for cancer and eye disease.
Abpro, which uses synthetic biology to speed up the manufacture of biomolecules for big pharma firms including Eli Lilly (NYSE: LLY) and Sanofi Genzyme (NYSE: SNY), announced the partnership with Essex Bio this morning. The company said that in addition to the $3.5 million from Essex, it’s also getting an undisclosed amount from other companies under the agreement.
